{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T05:57:58Z","timestamp":1777874278549,"version":"3.51.4"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001219","name":"Lymphoma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000102","name":"Health Resources and Services Administration","doi-asserted-by":"publisher","award":["T32 T32HP10027"],"award-info":[{"award-number":["T32 T32HP10027"]}],"id":[{"id":"10.13039\/100000102","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.hoc.2025.12.007","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T20:35:36Z","timestamp":1770669336000},"page":"247-256","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["New Developments in Hodgkin's Lymphoma"],"prefix":"10.1016","volume":"40","author":[{"given":"Katia M.","family":"Crisler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mallorie B.","family":"Heneghan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justine M.","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"S6","key":"10.1016\/j.hoc.2025.12.007_bib1","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30580","article-title":"Children\u2019s Oncology Group\u2019s 2023 blueprint for research: Hodgkin lymphoma","volume":"70","author":"Castellino","year":"2023","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"10.1016\/j.hoc.2025.12.007_bib2","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1002\/ajh.27470","article-title":"Hodgkin lymphoma: 2025 update on diagnosis, risk-stratification, and management","volume":"99","author":"Ansell","year":"2024","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.hoc.2025.12.007_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/hon.3239","article-title":"Classic Hodgkin lymphoma","volume":"42","author":"Kahn","year":"2024","journal-title":"Hematol Oncol"},{"issue":"1_suppl2","key":"10.1016\/j.hoc.2025.12.007_bib4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/00333549141291S203","article-title":"What are health disparities and health equity? We need to be clear","volume":"129","author":"Braveman","year":"2014","journal-title":"Publ Health Rep"},{"issue":"6","key":"10.1016\/j.hoc.2025.12.007_bib5","doi-asserted-by":"crossref","first-page":"765","DOI":"10.6004\/jnccn.2021.7048","article-title":"Improving health equity and reducing disparities in pediatric and Adolescent\/Young adult oncology: in Support of Clinical Practice Guidelines","volume":"19","author":"Kahn","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.hoc.2025.12.007_bib6","series-title":"What is health equity? And what difference does a definition make?","author":"Braverman","year":"2017"},{"issue":"1","key":"10.1016\/j.hoc.2025.12.007_bib7","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1016\/S2352-3026(21)00349-5","article-title":"Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children\u2019s oncology group trials","volume":"9","author":"Kahn","year":"2022","journal-title":"Lancet Haematol"},{"issue":"24","key":"10.1016\/j.hoc.2025.12.007_bib8","doi-asserted-by":"crossref","first-page":"4613","DOI":"10.1002\/cncr.33868","article-title":"Initial cancer treatment and survival in children, adolescents, and young adults with Hodgkin lymphoma: a population-based study","volume":"127","author":"Kahn","year":"2021","journal-title":"Cancer"},{"issue":"23","key":"10.1016\/j.hoc.2025.12.007_bib9","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1182\/blood.V126.23.2636.2636","article-title":"Outcomes in adolescents and Young Adults (AYA) with Hodgkin Lymphoma (HL) Treated on US Cooperative Group protocols: an adult intergroup (E2496) and Children\u2019s Oncology Group (COG AHOD0031) comparative analysis","volume":"126","author":"Henderson","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2025.12.007_bib10","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1080\/10428194.2018.1522435","article-title":"Inferior outcomes and treatment disparities in elderly patients with classical Hodgkin lymphoma: a national cancer data base analysis","volume":"60","author":"Major","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.hoc.2025.12.007_bib11","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1093\/annonc\/mdr578","article-title":"Racial disparities in Hodgkin\u2019s lymphoma: a comprehensive population-based analysis","volume":"23","author":"Evens","year":"2012","journal-title":"Ann Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.12.007_bib12","doi-asserted-by":"crossref","first-page":"4866","DOI":"10.1182\/blood-2018-99-119382","article-title":"Disparities in cancer-related mortality and long-term survival in adolescent and young adults with Hodgkin Lymphoma: a population-level analysis across the United States","volume":"132","author":"Kahn","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2025.12.007_bib13","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1089\/jayao.2021.0131","article-title":"Racial disparities in children, adolescents, and young adults with Hodgkin Lymphoma enrolled in the New York State Medicaid Program","volume":"11","author":"Kahn","year":"2022","journal-title":"J Adolesc Young Adult Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2025.12.007_bib14","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/1055-9965.EPI-15-0756","article-title":"Impact of treatment and insurance on socioeconomic disparities in survival after adolescent and young adult Hodgkin lymphoma: a population-based Study","volume":"25","author":"Keegan","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"10.1016\/j.hoc.2025.12.007_bib15","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/pbc.25802","article-title":"Racial and ethnic disparities in the pediatric hodgkin lymphoma population: pediatric HL Racial\/Ethnic disparities","volume":"63","author":"Grubb","year":"2016","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"10.1016\/j.hoc.2025.12.007_bib16","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1080\/10428194.2019.1680841","article-title":"Pediatric hodgkin lymphoma: disparities in survival by race","volume":"61","author":"Khullar","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"32","key":"10.1016\/j.hoc.2025.12.007_bib17","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1200\/JCO.19.00812","article-title":"Survival by race and ethnicity in pediatric and adolescent patients with Hodgkin Lymphoma: a Children\u2019s Oncology Group Study","volume":"37","author":"Kahn","year":"2019","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2025.12.007_bib18","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1158\/1055-9965.EPI-21-0103","article-title":"Impact of race, ethnicity, and socioeconomic status over time on the long-term survival of adolescent and young adult Hodgkin lymphoma survivors","volume":"30","author":"Berkman","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"17","key":"10.1016\/j.hoc.2025.12.007_bib19","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1002\/cncr.30089","article-title":"Racial disparities in the survival of American children, adolescents, and young adults with acute lymphoblastic leukemia, acute myelogenous leukemia, and Hodgkin lymphoma","volume":"122","author":"Kahn","year":"2016","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.hoc.2025.12.007_bib20","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1634\/theoncologist.2017-0541","article-title":"Long-term survival rates of patients with stage III\u2013IV hodgkin lymphoma according to age, sex, race, and socioeconomic status, 1984\u20132013","volume":"23","author":"Li","year":"2018","journal-title":"Oncologist"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.12.007_bib21","doi-asserted-by":"crossref","first-page":"10974","DOI":"10.1182\/blood-2022-167635","article-title":"The effects of social vulnerability on the prognosis and outcomes of Hodgkin\u2019s lymphoma in adults across the United States","volume":"140","author":"Wu","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2025.12.007_bib22","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1182\/bloodadvances.2024013956","article-title":"Socioeconomic, racial-ethnic, household, and infrastructural disparities of hematologic cancer outcomes in the United States","volume":"9","author":"Fei-Zhang","year":"2025","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.hoc.2025.12.007_bib23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/MPH.0000000000002776","article-title":"Impact of social disparities on 5-Year survival rates in pediatric hematologic malignancies","volume":"46","author":"Chalfant","year":"2024","journal-title":"J Pediatr Hematol Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2025.12.007_bib24","first-page":"1881","article-title":"Disparities in survival after Hodgkin lymphoma: a population-based study","volume":"20","author":"Keegan","year":"2009","journal-title":"Cancer Causes Control"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.12.007_bib25","doi-asserted-by":"crossref","first-page":"8046","DOI":"10.1182\/blood-2022-169477","article-title":"Impact of racial disparities and demographic factors on presentation, treatment, and survival amongst patients with Hodgkin lymphoma","volume":"140","author":"Didier","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2025.12.007_bib26","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1182\/bloodadvances.2024013532","article-title":"Medicaid coverage continuity is associated with lymphoma stage among children and adolescents\/young adults","volume":"9","author":"Zhang","year":"2025","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.hoc.2025.12.007_bib27","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1634\/theoncologist.2011-0126","article-title":"Cancer disparities in the context of medicaid insurance: a comparison of survival for acute myeloid leukemia and Hodgkin\u2019s lymphoma by medicaid enrollment","volume":"16","author":"Yung","year":"2011","journal-title":"Oncologist"},{"issue":"19","key":"10.1016\/j.hoc.2025.12.007_bib28","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1002\/cncr.29518","article-title":"Disparities in survival by insurance status in patients with Hodgkin lymphoma","volume":"121","author":"Parikh","year":"2015","journal-title":"Cancer"},{"issue":"32","key":"10.1016\/j.hoc.2025.12.007_bib29","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.1200\/JCO.2009.22.0038","article-title":"Survival disparities in patients with lymphoma according to place of residence and treatment provider: a population-based study","volume":"27","author":"Loberiza","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2025.12.007_bib30","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/leu.2017.66","article-title":"Impact of treatment site on disparities in outcome among adolescent and young adults with Hodgkin lymphoma","volume":"31","author":"Wolfson","year":"2017","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.hoc.2025.12.007_bib31","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/cncr.32584","article-title":"Association between facility volume and mortality of patients with classic Hodgkin lymphoma","volume":"126","author":"Goyal","year":"2020","journal-title":"Cancer"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.12.007_bib32","doi-asserted-by":"crossref","first-page":"7798","DOI":"10.1182\/blood-2024-199326","article-title":"Disparities in stage at diagnosis of Hodgkin\u2019s lymphoma among hispanics in the US: a population-based study","volume":"144","author":"Jeri Yabar","year":"2024","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2025.12.007_bib33","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1158\/1055-9965.EPI-24-0510","article-title":"Sociodemographic and socioeconomic factors correlate with late-stage pediatric hodgkin lymphoma and rhabdomyosarcoma: a report from the Children\u2019s Oncology Group registries","volume":"33","author":"Ou","year":"2024","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"24","key":"10.1016\/j.hoc.2025.12.007_bib34","doi-asserted-by":"crossref","first-page":"6179","DOI":"10.1002\/cncr.27684","article-title":"Association between insurance and socioeconomic status and risk of advanced stage Hodgkin lymphoma in adolescents and young adults","volume":"118","author":"Smith","year":"2012","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.hoc.2025.12.007_bib35","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1200\/JCO.2014.58.7543","article-title":"Treatment selection and outcomes in early-stage classical hodgkin lymphoma: analysis of the national cancer data base","volume":"33","author":"Olszewski","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2025.12.007_bib36","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.ijrobp.2015.06.039","article-title":"Early-stage classic hodgkin lymphoma: the utilization of radiation therapy and its impact on overall survival","volume":"93","author":"Parikh","year":"2015","journal-title":"Int J Radiat Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2025.12.007_bib37","doi-asserted-by":"crossref","first-page":"55","DOI":"10.14338\/IJPT-21-00012.1","article-title":"Evaluating disparities in proton radiation therapy use in AHOD1331, a Contemporary Children\u2019s Oncology Group trial for advanced-stage hodgkin lymphoma","volume":"8","author":"Mailhot Vega","year":"2022","journal-title":"Int J Part Ther"},{"issue":"9","key":"10.1016\/j.hoc.2025.12.007_bib38","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood.2023020052","article-title":"Representation of the population in need for pivotal clinical trials in lymphomas","volume":"142","author":"Casey","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.12.007_bib39","article-title":"Survival by race\/ethnicity on Children\u2019S Oncology Group trials for relapsed Hodgkin lymphoma","volume":"72","author":"Heneghan","year":"2025","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"10.1016\/j.hoc.2025.12.007_bib40","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/bjh.16197","article-title":"Closing the survivorship gap in children and adolescents with Hodgkin lymphoma","volume":"187","author":"Castellino","year":"2019","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.hoc.2025.12.007_bib41","first-page":"551","article-title":"Sociodemographic disparities in the occurrence of medical conditions among adolescent and young adult Hodgkin lymphoma survivors","volume":"29","author":"Keegan","year":"2018","journal-title":"Cancer Causes Control"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.12.007_bib42","doi-asserted-by":"crossref","first-page":"6359","DOI":"10.1182\/blood-2024-208944","article-title":"Neighborhood-level social determinants of health and cardiovascular burden in adolescent and young adult patients treated for Hodgkin lymphoma","volume":"144","author":"Rodriguez","year":"2024","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2025.12.007_bib43","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.clml.2015.07.638","article-title":"Trends and disparities in cardiovascular mortality among survivors of Hodgkin lymphoma","volume":"15","author":"Al-Kindi","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"17","key":"10.1016\/j.hoc.2025.12.007_bib44","doi-asserted-by":"crossref","first-page":"18281","DOI":"10.1002\/cam4.6426","article-title":"Disparities in pediatric cancer survivorship care: a systematic review","volume":"12","author":"Mobley","year":"2023","journal-title":"Cancer Med"},{"issue":"5","key":"10.1016\/j.hoc.2025.12.007_bib45","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkae071","article-title":"Financial distress and medical financial hardship among young adult survivors of blood cancer","volume":"8","author":"Parsons","year":"2024","journal-title":"JNCI Cancer Spectr"},{"issue":"18","key":"10.1016\/j.hoc.2025.12.007_bib46","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2206660","article-title":"Brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin\u2019s lymphoma","volume":"387","author":"Castellino","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.hoc.2025.12.007_bib47","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV hodgkin\u2019s lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.hoc.2025.12.007_bib48","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in advanced-stage classic Hodgkin\u2019s lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.12.007_bib49","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1182\/blood-2023-189652","article-title":"AHOD2131: a randomized phase 3 response-adapted trial comparing standard therapy with immuno-oncology therapy for children and adults with newly diagnosed stage I and II classic hodgkin lymphoma","volume":"142","author":"Henderson","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2025.12.007_bib50","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.trecan.2022.10.002","article-title":"A biopsychosocial model to understand racial disparities in the era of cancer immunotherapy","volume":"9","author":"Yao","year":"2023","journal-title":"Trends Cancer"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825001480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825001480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:27:19Z","timestamp":1777577239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858825001480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0889858825001480"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2025.12.007","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Developments in Hodgkin's Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2025.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}